nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—PTGS2—Triamcinolone—multiple sclerosis	0.129	0.424	CbGbCtD
Mesalazine—PTGS2—Betamethasone—multiple sclerosis	0.11	0.364	CbGbCtD
Mesalazine—PTGS2—Dexamethasone—multiple sclerosis	0.0641	0.212	CbGbCtD
Mesalazine—PPARG—leg—multiple sclerosis	0.00606	0.204	CbGeAlD
Mesalazine—Olsalazine—IFNG—multiple sclerosis	0.00417	0.794	CrCbGaD
Mesalazine—PTGS2—leg—multiple sclerosis	0.00309	0.104	CbGeAlD
Mesalazine—CHUK—cerebellum—multiple sclerosis	0.00165	0.0553	CbGeAlD
Mesalazine—CHUK—brain—multiple sclerosis	0.00134	0.0449	CbGeAlD
Mesalazine—IKBKB—nervous system—multiple sclerosis	0.00119	0.04	CbGeAlD
Mesalazine—IKBKB—central nervous system—multiple sclerosis	0.00114	0.0385	CbGeAlD
Mesalazine—IKBKB—cerebellum—multiple sclerosis	0.00112	0.0376	CbGeAlD
Mesalazine—PTGS2—Fluocinonide—Methylprednisolone—multiple sclerosis	0.0011	0.159	CbGdCrCtD
Mesalazine—PTGS2—Fluocinonide—Dexamethasone—multiple sclerosis	0.00108	0.156	CbGdCrCtD
Mesalazine—PTGS2—Fluocinonide—Betamethasone—multiple sclerosis	0.00108	0.156	CbGdCrCtD
Mesalazine—PTGS2—Fluocinonide—Triamcinolone—multiple sclerosis	0.00106	0.153	CbGdCrCtD
Mesalazine—MPO—spinal cord—multiple sclerosis	0.000989	0.0333	CbGeAlD
Mesalazine—ALOX5—nervous system—multiple sclerosis	0.000985	0.0331	CbGeAlD
Mesalazine—ALOX5—central nervous system—multiple sclerosis	0.000949	0.0319	CbGeAlD
Mesalazine—ALOX5—cerebellum—multiple sclerosis	0.000927	0.0312	CbGeAlD
Mesalazine—IKBKB—brain—multiple sclerosis	0.000909	0.0306	CbGeAlD
Mesalazine—MPO—nervous system—multiple sclerosis	0.000834	0.028	CbGeAlD
Mesalazine—MPO—central nervous system—multiple sclerosis	0.000803	0.027	CbGeAlD
Mesalazine—ALOX5—brain—multiple sclerosis	0.000753	0.0253	CbGeAlD
Mesalazine—PPARG—nervous system—multiple sclerosis	0.00074	0.0249	CbGeAlD
Mesalazine—PPARG—central nervous system—multiple sclerosis	0.000712	0.0239	CbGeAlD
Mesalazine—Diflunisal—ALB—multiple sclerosis	0.000695	0.132	CrCbGaD
Mesalazine—PTGS2—Fluticasone Propionate—Methylprednisolone—multiple sclerosis	0.000663	0.0958	CbGdCrCtD
Mesalazine—PTGS2—Fluticasone Propionate—Dexamethasone—multiple sclerosis	0.000653	0.0943	CbGdCrCtD
Mesalazine—PTGS2—Fluticasone Propionate—Betamethasone—multiple sclerosis	0.000653	0.0943	CbGdCrCtD
Mesalazine—PTGS2—Fluticasone Propionate—Triamcinolone—multiple sclerosis	0.000638	0.0921	CbGdCrCtD
Mesalazine—MPO—brain—multiple sclerosis	0.000637	0.0214	CbGeAlD
Mesalazine—PPARG—brain—multiple sclerosis	0.000565	0.019	CbGeAlD
Mesalazine—PTGS2—medulla oblongata—multiple sclerosis	0.000503	0.0169	CbGeAlD
Mesalazine—PTGS1—spinal cord—multiple sclerosis	0.000469	0.0158	CbGeAlD
Mesalazine—PTGS2—midbrain—multiple sclerosis	0.00046	0.0155	CbGeAlD
Mesalazine—PTGS2—spinal cord—multiple sclerosis	0.000449	0.0151	CbGeAlD
Mesalazine—PTGS1—nervous system—multiple sclerosis	0.000395	0.0133	CbGeAlD
Mesalazine—Salicylic acid—ALB—multiple sclerosis	0.000386	0.0736	CrCbGaD
Mesalazine—PTGS1—central nervous system—multiple sclerosis	0.000381	0.0128	CbGeAlD
Mesalazine—PTGS2—nervous system—multiple sclerosis	0.000378	0.0127	CbGeAlD
Mesalazine—PTGS2—central nervous system—multiple sclerosis	0.000364	0.0122	CbGeAlD
Mesalazine—PTGS2—cerebellum—multiple sclerosis	0.000356	0.012	CbGeAlD
Mesalazine—PTGS1—brain—multiple sclerosis	0.000302	0.0102	CbGeAlD
Mesalazine—PTGS2—brain—multiple sclerosis	0.000289	0.00971	CbGeAlD
Mesalazine—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000164	0.000489	CcSEcCtD
Mesalazine—Epistaxis—Methotrexate—multiple sclerosis	0.000164	0.000489	CcSEcCtD
Mesalazine—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000164	0.000489	CcSEcCtD
Mesalazine—Paraesthesia—Prednisolone—multiple sclerosis	0.000164	0.000489	CcSEcCtD
Mesalazine—Tachycardia—Triamcinolone—multiple sclerosis	0.000164	0.000489	CcSEcCtD
Mesalazine—Mental disorder—Prednisone—multiple sclerosis	0.000164	0.000488	CcSEcCtD
Mesalazine—Nausea—Azathioprine—multiple sclerosis	0.000164	0.000488	CcSEcCtD
Mesalazine—Tachycardia—Methylprednisolone—multiple sclerosis	0.000164	0.000488	CcSEcCtD
Mesalazine—Skin disorder—Methylprednisolone—multiple sclerosis	0.000163	0.000485	CcSEcCtD
Mesalazine—Erythema—Prednisone—multiple sclerosis	0.000163	0.000485	CcSEcCtD
Mesalazine—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000162	0.000484	CcSEcCtD
Mesalazine—Agranulocytosis—Methotrexate—multiple sclerosis	0.000162	0.000484	CcSEcCtD
Mesalazine—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000162	0.000483	CcSEcCtD
Mesalazine—Hypertension—Dexamethasone—multiple sclerosis	0.000161	0.000481	CcSEcCtD
Mesalazine—Hypertension—Betamethasone—multiple sclerosis	0.000161	0.000481	CcSEcCtD
Mesalazine—Asthenia—Mitoxantrone—multiple sclerosis	0.00016	0.000476	CcSEcCtD
Mesalazine—Myalgia—Dexamethasone—multiple sclerosis	0.000159	0.000474	CcSEcCtD
Mesalazine—Myalgia—Betamethasone—multiple sclerosis	0.000159	0.000474	CcSEcCtD
Mesalazine—Anxiety—Dexamethasone—multiple sclerosis	0.000158	0.000472	CcSEcCtD
Mesalazine—Anxiety—Betamethasone—multiple sclerosis	0.000158	0.000472	CcSEcCtD
Mesalazine—Discomfort—Dexamethasone—multiple sclerosis	0.000157	0.000468	CcSEcCtD
Mesalazine—Discomfort—Betamethasone—multiple sclerosis	0.000157	0.000468	CcSEcCtD
Mesalazine—Haemoglobin—Methotrexate—multiple sclerosis	0.000157	0.000468	CcSEcCtD
Mesalazine—Hypotension—Methylprednisolone—multiple sclerosis	0.000157	0.000467	CcSEcCtD
Mesalazine—Pain—Prednisolone—multiple sclerosis	0.000156	0.000466	CcSEcCtD
Mesalazine—Haemorrhage—Methotrexate—multiple sclerosis	0.000156	0.000465	CcSEcCtD
Mesalazine—Hepatitis—Methotrexate—multiple sclerosis	0.000156	0.000465	CcSEcCtD
Mesalazine—Pharyngitis—Methotrexate—multiple sclerosis	0.000155	0.000462	CcSEcCtD
Mesalazine—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000154	0.00046	CcSEcCtD
Mesalazine—Vision blurred—Prednisone—multiple sclerosis	0.000153	0.000457	CcSEcCtD
Mesalazine—Urethral disorder—Methotrexate—multiple sclerosis	0.000153	0.000456	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000153	0.000456	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000153	0.000455	CcSEcCtD
Mesalazine—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000152	0.000454	CcSEcCtD
Mesalazine—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000152	0.000454	CcSEcCtD
Mesalazine—Oedema—Dexamethasone—multiple sclerosis	0.000152	0.000454	CcSEcCtD
Mesalazine—Oedema—Betamethasone—multiple sclerosis	0.000152	0.000454	CcSEcCtD
Mesalazine—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000152	0.000454	CcSEcCtD
Mesalazine—Insomnia—Triamcinolone—multiple sclerosis	0.000152	0.000453	CcSEcCtD
Mesalazine—Insomnia—Methylprednisolone—multiple sclerosis	0.000152	0.000452	CcSEcCtD
Mesalazine—Infection—Betamethasone—multiple sclerosis	0.000151	0.000451	CcSEcCtD
Mesalazine—Infection—Dexamethasone—multiple sclerosis	0.000151	0.000451	CcSEcCtD
Mesalazine—Ill-defined disorder—Prednisone—multiple sclerosis	0.000151	0.00045	CcSEcCtD
Mesalazine—Paraesthesia—Triamcinolone—multiple sclerosis	0.000151	0.00045	CcSEcCtD
Mesalazine—Feeling abnormal—Prednisolone—multiple sclerosis	0.000151	0.000449	CcSEcCtD
Mesalazine—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000151	0.000449	CcSEcCtD
Mesalazine—Anaemia—Prednisone—multiple sclerosis	0.00015	0.000448	CcSEcCtD
Mesalazine—Shock—Dexamethasone—multiple sclerosis	0.00015	0.000447	CcSEcCtD
Mesalazine—Shock—Betamethasone—multiple sclerosis	0.00015	0.000447	CcSEcCtD
Mesalazine—Dyspnoea—Triamcinolone—multiple sclerosis	0.00015	0.000446	CcSEcCtD
Mesalazine—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000149	0.000445	CcSEcCtD
Mesalazine—Nervous system disorder—Betamethasone—multiple sclerosis	0.000149	0.000445	CcSEcCtD
Mesalazine—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000149	0.000445	CcSEcCtD
Mesalazine—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000149	0.000445	CcSEcCtD
Mesalazine—Tachycardia—Dexamethasone—multiple sclerosis	0.000149	0.000443	CcSEcCtD
Mesalazine—Tachycardia—Betamethasone—multiple sclerosis	0.000149	0.000443	CcSEcCtD
Mesalazine—Angioedema—Prednisone—multiple sclerosis	0.000149	0.000443	CcSEcCtD
Mesalazine—Dyspepsia—Triamcinolone—multiple sclerosis	0.000148	0.000441	CcSEcCtD
Mesalazine—Erythema multiforme—Methotrexate—multiple sclerosis	0.000148	0.00044	CcSEcCtD
Mesalazine—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000148	0.00044	CcSEcCtD
Mesalazine—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000147	0.000439	CcSEcCtD
Mesalazine—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000147	0.000439	CcSEcCtD
Mesalazine—Malaise—Prednisone—multiple sclerosis	0.000147	0.000437	CcSEcCtD
Mesalazine—Vertigo—Prednisone—multiple sclerosis	0.000146	0.000435	CcSEcCtD
Mesalazine—Eye disorder—Methotrexate—multiple sclerosis	0.000146	0.000435	CcSEcCtD
Mesalazine—Syncope—Prednisone—multiple sclerosis	0.000146	0.000435	CcSEcCtD
Mesalazine—Tinnitus—Methotrexate—multiple sclerosis	0.000146	0.000434	CcSEcCtD
Mesalazine—Anorexia—Dexamethasone—multiple sclerosis	0.000145	0.000433	CcSEcCtD
Mesalazine—Anorexia—Betamethasone—multiple sclerosis	0.000145	0.000433	CcSEcCtD
Mesalazine—Urticaria—Prednisolone—multiple sclerosis	0.000145	0.000432	CcSEcCtD
Mesalazine—Cardiac disorder—Methotrexate—multiple sclerosis	0.000145	0.000432	CcSEcCtD
Mesalazine—Fatigue—Triamcinolone—multiple sclerosis	0.000145	0.000432	CcSEcCtD
Mesalazine—Fatigue—Methylprednisolone—multiple sclerosis	0.000145	0.000431	CcSEcCtD
Mesalazine—Pain—Triamcinolone—multiple sclerosis	0.000144	0.000428	CcSEcCtD
Mesalazine—Loss of consciousness—Prednisone—multiple sclerosis	0.000143	0.000426	CcSEcCtD
Mesalazine—Hypotension—Betamethasone—multiple sclerosis	0.000142	0.000424	CcSEcCtD
Mesalazine—Hypotension—Dexamethasone—multiple sclerosis	0.000142	0.000424	CcSEcCtD
Mesalazine—Angiopathy—Methotrexate—multiple sclerosis	0.000142	0.000422	CcSEcCtD
Mesalazine—Vomiting—Mitoxantrone—multiple sclerosis	0.000142	0.000422	CcSEcCtD
Mesalazine—Immune system disorder—Methotrexate—multiple sclerosis	0.000141	0.00042	CcSEcCtD
Mesalazine—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000141	0.000419	CcSEcCtD
Mesalazine—Hypertension—Prednisone—multiple sclerosis	0.00014	0.000418	CcSEcCtD
Mesalazine—Rash—Mitoxantrone—multiple sclerosis	0.00014	0.000418	CcSEcCtD
Mesalazine—Dermatitis—Mitoxantrone—multiple sclerosis	0.00014	0.000418	CcSEcCtD
Mesalazine—Chills—Methotrexate—multiple sclerosis	0.00014	0.000418	CcSEcCtD
Mesalazine—Headache—Mitoxantrone—multiple sclerosis	0.00014	0.000416	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000139	0.000414	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000139	0.000414	CcSEcCtD
Mesalazine—Myalgia—Prednisone—multiple sclerosis	0.000138	0.000413	CcSEcCtD
Mesalazine—Arthralgia—Prednisone—multiple sclerosis	0.000138	0.000413	CcSEcCtD
Mesalazine—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000138	0.000413	CcSEcCtD
Mesalazine—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000138	0.000412	CcSEcCtD
Mesalazine—Anxiety—Prednisone—multiple sclerosis	0.000138	0.000411	CcSEcCtD
Mesalazine—Alopecia—Methotrexate—multiple sclerosis	0.000138	0.000411	CcSEcCtD
Mesalazine—Insomnia—Betamethasone—multiple sclerosis	0.000138	0.000411	CcSEcCtD
Mesalazine—Insomnia—Dexamethasone—multiple sclerosis	0.000138	0.000411	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000138	0.00041	CcSEcCtD
Mesalazine—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000137	0.000408	CcSEcCtD
Mesalazine—Paraesthesia—Betamethasone—multiple sclerosis	0.000137	0.000408	CcSEcCtD
Mesalazine—Paraesthesia—Dexamethasone—multiple sclerosis	0.000137	0.000408	CcSEcCtD
Mesalazine—Discomfort—Prednisone—multiple sclerosis	0.000137	0.000408	CcSEcCtD
Mesalazine—Mental disorder—Methotrexate—multiple sclerosis	0.000137	0.000408	CcSEcCtD
Mesalazine—Erythema—Methotrexate—multiple sclerosis	0.000136	0.000405	CcSEcCtD
Mesalazine—Hypersensitivity—Prednisolone—multiple sclerosis	0.000135	0.000401	CcSEcCtD
Mesalazine—Dyspepsia—Betamethasone—multiple sclerosis	0.000134	0.0004	CcSEcCtD
Mesalazine—Dyspepsia—Dexamethasone—multiple sclerosis	0.000134	0.0004	CcSEcCtD
Mesalazine—Urticaria—Triamcinolone—multiple sclerosis	0.000133	0.000398	CcSEcCtD
Mesalazine—Urticaria—Methylprednisolone—multiple sclerosis	0.000133	0.000397	CcSEcCtD
Mesalazine—Dysgeusia—Methotrexate—multiple sclerosis	0.000133	0.000397	CcSEcCtD
Mesalazine—Body temperature increased—Triamcinolone—multiple sclerosis	0.000133	0.000396	CcSEcCtD
Mesalazine—Anaphylactic shock—Prednisone—multiple sclerosis	0.000133	0.000396	CcSEcCtD
Mesalazine—Oedema—Prednisone—multiple sclerosis	0.000133	0.000396	CcSEcCtD
Mesalazine—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000133	0.000395	CcSEcCtD
Mesalazine—Decreased appetite—Dexamethasone—multiple sclerosis	0.000133	0.000395	CcSEcCtD
Mesalazine—Decreased appetite—Betamethasone—multiple sclerosis	0.000133	0.000395	CcSEcCtD
Mesalazine—Nausea—Mitoxantrone—multiple sclerosis	0.000132	0.000394	CcSEcCtD
Mesalazine—Infection—Prednisone—multiple sclerosis	0.000132	0.000393	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000132	0.000392	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000132	0.000392	CcSEcCtD
Mesalazine—Back pain—Methotrexate—multiple sclerosis	0.000132	0.000392	CcSEcCtD
Mesalazine—Fatigue—Dexamethasone—multiple sclerosis	0.000131	0.000392	CcSEcCtD
Mesalazine—Fatigue—Betamethasone—multiple sclerosis	0.000131	0.000392	CcSEcCtD
Mesalazine—Shock—Prednisone—multiple sclerosis	0.000131	0.000389	CcSEcCtD
Mesalazine—Pain—Dexamethasone—multiple sclerosis	0.00013	0.000388	CcSEcCtD
Mesalazine—Pain—Betamethasone—multiple sclerosis	0.00013	0.000388	CcSEcCtD
Mesalazine—Nervous system disorder—Prednisone—multiple sclerosis	0.00013	0.000388	CcSEcCtD
Mesalazine—Tachycardia—Prednisone—multiple sclerosis	0.00013	0.000386	CcSEcCtD
Mesalazine—Skin disorder—Prednisone—multiple sclerosis	0.000129	0.000384	CcSEcCtD
Mesalazine—Hyperhidrosis—Prednisone—multiple sclerosis	0.000128	0.000382	CcSEcCtD
Mesalazine—Vision blurred—Methotrexate—multiple sclerosis	0.000128	0.000382	CcSEcCtD
Mesalazine—Anorexia—Prednisone—multiple sclerosis	0.000127	0.000377	CcSEcCtD
Mesalazine—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000126	0.000376	CcSEcCtD
Mesalazine—Anaemia—Methotrexate—multiple sclerosis	0.000126	0.000374	CcSEcCtD
Mesalazine—Feeling abnormal—Betamethasone—multiple sclerosis	0.000126	0.000374	CcSEcCtD
Mesalazine—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000126	0.000374	CcSEcCtD
Mesalazine—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000125	0.000371	CcSEcCtD
Mesalazine—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000125	0.000371	CcSEcCtD
Mesalazine—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000124	0.000369	CcSEcCtD
Mesalazine—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000124	0.000368	CcSEcCtD
Mesalazine—Malaise—Methotrexate—multiple sclerosis	0.000123	0.000365	CcSEcCtD
Mesalazine—Vertigo—Methotrexate—multiple sclerosis	0.000122	0.000364	CcSEcCtD
Mesalazine—Leukopenia—Methotrexate—multiple sclerosis	0.000122	0.000363	CcSEcCtD
Mesalazine—Urticaria—Dexamethasone—multiple sclerosis	0.000121	0.000361	CcSEcCtD
Mesalazine—Urticaria—Betamethasone—multiple sclerosis	0.000121	0.000361	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000121	0.00036	CcSEcCtD
Mesalazine—Dizziness—Prednisolone—multiple sclerosis	0.000121	0.00036	CcSEcCtD
Mesalazine—Asthenia—Triamcinolone—multiple sclerosis	0.000121	0.000359	CcSEcCtD
Mesalazine—Abdominal pain—Dexamethasone—multiple sclerosis	0.000121	0.000359	CcSEcCtD
Mesalazine—Body temperature increased—Dexamethasone—multiple sclerosis	0.000121	0.000359	CcSEcCtD
Mesalazine—Abdominal pain—Betamethasone—multiple sclerosis	0.000121	0.000359	CcSEcCtD
Mesalazine—Body temperature increased—Betamethasone—multiple sclerosis	0.000121	0.000359	CcSEcCtD
Mesalazine—Asthenia—Methylprednisolone—multiple sclerosis	0.00012	0.000358	CcSEcCtD
Mesalazine—Insomnia—Prednisone—multiple sclerosis	0.00012	0.000358	CcSEcCtD
Mesalazine—Paraesthesia—Prednisone—multiple sclerosis	0.000119	0.000355	CcSEcCtD
Mesalazine—Pruritus—Triamcinolone—multiple sclerosis	0.000119	0.000354	CcSEcCtD
Mesalazine—Cough—Methotrexate—multiple sclerosis	0.000119	0.000353	CcSEcCtD
Mesalazine—Pruritus—Methylprednisolone—multiple sclerosis	0.000119	0.000353	CcSEcCtD
Mesalazine—Dyspepsia—Prednisone—multiple sclerosis	0.000117	0.000348	CcSEcCtD
Mesalazine—Arthralgia—Methotrexate—multiple sclerosis	0.000116	0.000345	CcSEcCtD
Mesalazine—Myalgia—Methotrexate—multiple sclerosis	0.000116	0.000345	CcSEcCtD
Mesalazine—Chest pain—Methotrexate—multiple sclerosis	0.000116	0.000345	CcSEcCtD
Mesalazine—Decreased appetite—Prednisone—multiple sclerosis	0.000115	0.000344	CcSEcCtD
Mesalazine—Rash—Prednisolone—multiple sclerosis	0.000115	0.000343	CcSEcCtD
Mesalazine—Dermatitis—Prednisolone—multiple sclerosis	0.000115	0.000343	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000115	0.000342	CcSEcCtD
Mesalazine—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000115	0.000342	CcSEcCtD
Mesalazine—Fatigue—Prednisone—multiple sclerosis	0.000114	0.000341	CcSEcCtD
Mesalazine—Headache—Prednisolone—multiple sclerosis	0.000114	0.000341	CcSEcCtD
Mesalazine—Discomfort—Methotrexate—multiple sclerosis	0.000114	0.000341	CcSEcCtD
Mesalazine—Constipation—Prednisone—multiple sclerosis	0.000114	0.000338	CcSEcCtD
Mesalazine—Confusional state—Methotrexate—multiple sclerosis	0.000112	0.000333	CcSEcCtD
Mesalazine—Dizziness—Triamcinolone—multiple sclerosis	0.000111	0.000331	CcSEcCtD
Mesalazine—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000111	0.000331	CcSEcCtD
Mesalazine—Dizziness—Methylprednisolone—multiple sclerosis	0.000111	0.00033	CcSEcCtD
Mesalazine—Infection—Methotrexate—multiple sclerosis	0.00011	0.000328	CcSEcCtD
Mesalazine—Feeling abnormal—Prednisone—multiple sclerosis	0.000109	0.000326	CcSEcCtD
Mesalazine—Asthenia—Betamethasone—multiple sclerosis	0.000109	0.000326	CcSEcCtD
Mesalazine—Asthenia—Dexamethasone—multiple sclerosis	0.000109	0.000326	CcSEcCtD
Mesalazine—Nervous system disorder—Methotrexate—multiple sclerosis	0.000109	0.000324	CcSEcCtD
Mesalazine—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000109	0.000324	CcSEcCtD
Mesalazine—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000109	0.000323	CcSEcCtD
Mesalazine—Nausea—Prednisolone—multiple sclerosis	0.000109	0.000323	CcSEcCtD
Mesalazine—Pruritus—Betamethasone—multiple sclerosis	0.000108	0.000321	CcSEcCtD
Mesalazine—Pruritus—Dexamethasone—multiple sclerosis	0.000108	0.000321	CcSEcCtD
Mesalazine—Skin disorder—Methotrexate—multiple sclerosis	0.000108	0.000321	CcSEcCtD
Mesalazine—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000107	0.00032	CcSEcCtD
Mesalazine—Vomiting—Triamcinolone—multiple sclerosis	0.000107	0.000318	CcSEcCtD
Mesalazine—Vomiting—Methylprednisolone—multiple sclerosis	0.000107	0.000318	CcSEcCtD
Mesalazine—Rash—Triamcinolone—multiple sclerosis	0.000106	0.000316	CcSEcCtD
Mesalazine—Dermatitis—Triamcinolone—multiple sclerosis	0.000106	0.000315	CcSEcCtD
Mesalazine—Anorexia—Methotrexate—multiple sclerosis	0.000106	0.000315	CcSEcCtD
Mesalazine—Rash—Methylprednisolone—multiple sclerosis	0.000106	0.000315	CcSEcCtD
Mesalazine—Dermatitis—Methylprednisolone—multiple sclerosis	0.000106	0.000315	CcSEcCtD
Mesalazine—Urticaria—Prednisone—multiple sclerosis	0.000105	0.000314	CcSEcCtD
Mesalazine—Headache—Triamcinolone—multiple sclerosis	0.000105	0.000314	CcSEcCtD
Mesalazine—Headache—Methylprednisolone—multiple sclerosis	0.000105	0.000313	CcSEcCtD
Mesalazine—Body temperature increased—Prednisone—multiple sclerosis	0.000105	0.000313	CcSEcCtD
Mesalazine—Abdominal pain—Prednisone—multiple sclerosis	0.000105	0.000313	CcSEcCtD
Mesalazine—Diarrhoea—Betamethasone—multiple sclerosis	0.000104	0.000311	CcSEcCtD
Mesalazine—Diarrhoea—Dexamethasone—multiple sclerosis	0.000104	0.000311	CcSEcCtD
Mesalazine—Hypotension—Methotrexate—multiple sclerosis	0.000104	0.000309	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000101	0.000301	CcSEcCtD
Mesalazine—Dizziness—Dexamethasone—multiple sclerosis	0.000101	0.0003	CcSEcCtD
Mesalazine—Dizziness—Betamethasone—multiple sclerosis	0.000101	0.0003	CcSEcCtD
Mesalazine—Insomnia—Methotrexate—multiple sclerosis	0.0001	0.000299	CcSEcCtD
Mesalazine—Nausea—Triamcinolone—multiple sclerosis	9.98e-05	0.000297	CcSEcCtD
Mesalazine—Paraesthesia—Methotrexate—multiple sclerosis	9.96e-05	0.000297	CcSEcCtD
Mesalazine—Nausea—Methylprednisolone—multiple sclerosis	9.96e-05	0.000297	CcSEcCtD
Mesalazine—Dyspnoea—Methotrexate—multiple sclerosis	9.89e-05	0.000295	CcSEcCtD
Mesalazine—Somnolence—Methotrexate—multiple sclerosis	9.86e-05	0.000294	CcSEcCtD
Mesalazine—Hypersensitivity—Prednisone—multiple sclerosis	9.78e-05	0.000291	CcSEcCtD
Mesalazine—Dyspepsia—Methotrexate—multiple sclerosis	9.77e-05	0.000291	CcSEcCtD
Mesalazine—Vomiting—Betamethasone—multiple sclerosis	9.69e-05	0.000289	CcSEcCtD
Mesalazine—Vomiting—Dexamethasone—multiple sclerosis	9.69e-05	0.000289	CcSEcCtD
Mesalazine—Decreased appetite—Methotrexate—multiple sclerosis	9.64e-05	0.000287	CcSEcCtD
Mesalazine—Rash—Dexamethasone—multiple sclerosis	9.61e-05	0.000286	CcSEcCtD
Mesalazine—Rash—Betamethasone—multiple sclerosis	9.61e-05	0.000286	CcSEcCtD
Mesalazine—Dermatitis—Betamethasone—multiple sclerosis	9.6e-05	0.000286	CcSEcCtD
Mesalazine—Dermatitis—Dexamethasone—multiple sclerosis	9.6e-05	0.000286	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Methotrexate—multiple sclerosis	9.58e-05	0.000285	CcSEcCtD
Mesalazine—Fatigue—Methotrexate—multiple sclerosis	9.57e-05	0.000285	CcSEcCtD
Mesalazine—Headache—Betamethasone—multiple sclerosis	9.55e-05	0.000285	CcSEcCtD
Mesalazine—Headache—Dexamethasone—multiple sclerosis	9.55e-05	0.000285	CcSEcCtD
Mesalazine—Asthenia—Prednisone—multiple sclerosis	9.53e-05	0.000284	CcSEcCtD
Mesalazine—Pain—Methotrexate—multiple sclerosis	9.49e-05	0.000283	CcSEcCtD
Mesalazine—Pruritus—Prednisone—multiple sclerosis	9.39e-05	0.00028	CcSEcCtD
Mesalazine—Feeling abnormal—Methotrexate—multiple sclerosis	9.14e-05	0.000272	CcSEcCtD
Mesalazine—Diarrhoea—Prednisone—multiple sclerosis	9.08e-05	0.000271	CcSEcCtD
Mesalazine—Gastrointestinal pain—Methotrexate—multiple sclerosis	9.07e-05	0.00027	CcSEcCtD
Mesalazine—Nausea—Dexamethasone—multiple sclerosis	9.06e-05	0.00027	CcSEcCtD
Mesalazine—Nausea—Betamethasone—multiple sclerosis	9.06e-05	0.00027	CcSEcCtD
Mesalazine—Urticaria—Methotrexate—multiple sclerosis	8.81e-05	0.000263	CcSEcCtD
Mesalazine—Dizziness—Prednisone—multiple sclerosis	8.78e-05	0.000262	CcSEcCtD
Mesalazine—Body temperature increased—Methotrexate—multiple sclerosis	8.77e-05	0.000261	CcSEcCtD
Mesalazine—Abdominal pain—Methotrexate—multiple sclerosis	8.77e-05	0.000261	CcSEcCtD
Mesalazine—Vomiting—Prednisone—multiple sclerosis	8.44e-05	0.000252	CcSEcCtD
Mesalazine—Rash—Prednisone—multiple sclerosis	8.37e-05	0.000249	CcSEcCtD
Mesalazine—Dermatitis—Prednisone—multiple sclerosis	8.36e-05	0.000249	CcSEcCtD
Mesalazine—Headache—Prednisone—multiple sclerosis	8.32e-05	0.000248	CcSEcCtD
Mesalazine—Hypersensitivity—Methotrexate—multiple sclerosis	8.17e-05	0.000244	CcSEcCtD
Mesalazine—Asthenia—Methotrexate—multiple sclerosis	7.96e-05	0.000237	CcSEcCtD
Mesalazine—Nausea—Prednisone—multiple sclerosis	7.89e-05	0.000235	CcSEcCtD
Mesalazine—Pruritus—Methotrexate—multiple sclerosis	7.85e-05	0.000234	CcSEcCtD
Mesalazine—Diarrhoea—Methotrexate—multiple sclerosis	7.59e-05	0.000226	CcSEcCtD
Mesalazine—Dizziness—Methotrexate—multiple sclerosis	7.34e-05	0.000219	CcSEcCtD
Mesalazine—Vomiting—Methotrexate—multiple sclerosis	7.05e-05	0.00021	CcSEcCtD
Mesalazine—Rash—Methotrexate—multiple sclerosis	7e-05	0.000208	CcSEcCtD
Mesalazine—Dermatitis—Methotrexate—multiple sclerosis	6.99e-05	0.000208	CcSEcCtD
Mesalazine—Headache—Methotrexate—multiple sclerosis	6.95e-05	0.000207	CcSEcCtD
Mesalazine—Nausea—Methotrexate—multiple sclerosis	6.59e-05	0.000196	CcSEcCtD
Mesalazine—CHUK—Signaling by ERBB4—IL6—multiple sclerosis	5.74e-05	0.00018	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CD86—multiple sclerosis	5.71e-05	0.000179	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	5.7e-05	0.000178	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CD40LG—multiple sclerosis	5.6e-05	0.000175	CbGpPWpGaD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—IL6—multiple sclerosis	5.59e-05	0.000175	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—HLA-B—multiple sclerosis	5.54e-05	0.000173	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—MYC—multiple sclerosis	5.54e-05	0.000173	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CD8A—multiple sclerosis	5.53e-05	0.000173	CbGpPWpGaD
Mesalazine—IKBKB—Toll-Like Receptors Cascades—IL6—multiple sclerosis	5.53e-05	0.000173	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—TGFB1—multiple sclerosis	5.52e-05	0.000173	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RGS1—multiple sclerosis	5.51e-05	0.000172	CbGpPWpGaD
Mesalazine—CHUK—Downstream signal transduction—IL6—multiple sclerosis	5.48e-05	0.000171	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR—IL6—multiple sclerosis	5.45e-05	0.000171	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—IL1B—multiple sclerosis	5.45e-05	0.000171	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—HLA-A—multiple sclerosis	5.44e-05	0.00017	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—IL2—multiple sclerosis	5.43e-05	0.00017	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB2—IL6—multiple sclerosis	5.43e-05	0.00017	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—MAPK1—multiple sclerosis	5.42e-05	0.00017	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—IL6—multiple sclerosis	5.4e-05	0.000169	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—TNFAIP3—multiple sclerosis	5.39e-05	0.000169	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP24A1—multiple sclerosis	5.39e-05	0.000169	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP27B1—multiple sclerosis	5.39e-05	0.000169	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD28—multiple sclerosis	5.35e-05	0.000167	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HLA-B—multiple sclerosis	5.32e-05	0.000167	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CXCL13—multiple sclerosis	5.27e-05	0.000165	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCR1—multiple sclerosis	5.27e-05	0.000165	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	5.27e-05	0.000165	CbGpPWpGaD
Mesalazine—PTGS2—Selenium Micronutrient Network—IL6—multiple sclerosis	5.26e-05	0.000165	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PTPRC—multiple sclerosis	5.25e-05	0.000164	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CCR2—multiple sclerosis	5.25e-05	0.000164	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—GPR65—multiple sclerosis	5.23e-05	0.000164	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—TLR4—multiple sclerosis	5.18e-05	0.000162	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—TNF—multiple sclerosis	5.16e-05	0.000161	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—RRM1—multiple sclerosis	5.14e-05	0.000161	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—IL6—multiple sclerosis	5.08e-05	0.000159	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—IL6—multiple sclerosis	5.08e-05	0.000159	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—IL6—multiple sclerosis	5.08e-05	0.000159	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HLA-DPB1—multiple sclerosis	5.08e-05	0.000159	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—STAT3—multiple sclerosis	5.04e-05	0.000158	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—IL6—multiple sclerosis	5.03e-05	0.000158	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—IL6—multiple sclerosis	4.99e-05	0.000156	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—HLA-DRB1—multiple sclerosis	4.97e-05	0.000155	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—IL6—multiple sclerosis	4.97e-05	0.000155	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—STAT3—multiple sclerosis	4.95e-05	0.000155	CbGpPWpGaD
Mesalazine—CHUK—Disease—CD28—multiple sclerosis	4.94e-05	0.000155	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HLA-A—multiple sclerosis	4.93e-05	0.000154	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GPC5—multiple sclerosis	4.93e-05	0.000154	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	4.89e-05	0.000153	CbGpPWpGaD
Mesalazine—PPARG—Circadian rythm related genes—IL6—multiple sclerosis	4.89e-05	0.000153	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD40—multiple sclerosis	4.88e-05	0.000153	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ITGA4—multiple sclerosis	4.88e-05	0.000153	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—TYK2—multiple sclerosis	4.87e-05	0.000152	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD28—multiple sclerosis	4.85e-05	0.000152	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IFNB1—multiple sclerosis	4.85e-05	0.000152	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CTLA4—multiple sclerosis	4.81e-05	0.000151	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CD80—multiple sclerosis	4.78e-05	0.00015	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCR1—multiple sclerosis	4.78e-05	0.00015	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CXCL13—multiple sclerosis	4.78e-05	0.00015	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—ICAM1—multiple sclerosis	4.77e-05	0.000149	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PTPRC—multiple sclerosis	4.76e-05	0.000149	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CCR2—multiple sclerosis	4.76e-05	0.000149	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—TLR4—multiple sclerosis	4.7e-05	0.000147	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—IL6—multiple sclerosis	4.61e-05	0.000144	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HLA-DPB1—multiple sclerosis	4.6e-05	0.000144	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CD80—multiple sclerosis	4.59e-05	0.000144	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—MAPK1—multiple sclerosis	4.58e-05	0.000143	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—STAT3—multiple sclerosis	4.57e-05	0.000143	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HLA-DRB1—multiple sclerosis	4.51e-05	0.000141	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—MAPK1—multiple sclerosis	4.5e-05	0.000141	CbGpPWpGaD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—IL6—multiple sclerosis	4.5e-05	0.000141	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—STAT3—multiple sclerosis	4.49e-05	0.000141	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	4.46e-05	0.00014	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ITGA4—multiple sclerosis	4.43e-05	0.000139	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD40—multiple sclerosis	4.43e-05	0.000139	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IFNB1—multiple sclerosis	4.4e-05	0.000138	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CTLA4—multiple sclerosis	4.36e-05	0.000137	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CD80—multiple sclerosis	4.34e-05	0.000136	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—ICAM1—multiple sclerosis	4.32e-05	0.000135	CbGpPWpGaD
Mesalazine—CHUK—Immune System—VCAM1—multiple sclerosis	4.25e-05	0.000133	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HLA-DQA1—multiple sclerosis	4.24e-05	0.000133	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—BCHE—multiple sclerosis	4.22e-05	0.000132	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CD80—multiple sclerosis	4.16e-05	0.00013	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—IL6—multiple sclerosis	4.16e-05	0.00013	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—MAPK1—multiple sclerosis	4.15e-05	0.00013	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—APOE—multiple sclerosis	4.1e-05	0.000128	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—MAPK1—multiple sclerosis	4.08e-05	0.000128	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—RRM1—multiple sclerosis	4.08e-05	0.000128	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—VDR—multiple sclerosis	4.08e-05	0.000128	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—TYK2—multiple sclerosis	4.04e-05	0.000126	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.99e-05	0.000125	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HLA-DQB1—multiple sclerosis	3.96e-05	0.000124	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—VCAM1—multiple sclerosis	3.85e-05	0.000121	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HLA-DQA1—multiple sclerosis	3.84e-05	0.00012	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—MMP9—multiple sclerosis	3.83e-05	0.00012	CbGpPWpGaD
Mesalazine—PTGS2—Disease—RPL5—multiple sclerosis	3.83e-05	0.00012	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD86—multiple sclerosis	3.82e-05	0.000119	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	3.77e-05	0.000118	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	3.76e-05	0.000118	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCL3—multiple sclerosis	3.76e-05	0.000118	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD40LG—multiple sclerosis	3.74e-05	0.000117	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD8A—multiple sclerosis	3.7e-05	0.000116	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	3.69e-05	0.000115	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SLC11A1—multiple sclerosis	3.66e-05	0.000115	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—TYK2—multiple sclerosis	3.66e-05	0.000115	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CD4—multiple sclerosis	3.65e-05	0.000114	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTGER4—multiple sclerosis	3.62e-05	0.000113	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HLA-DQB1—multiple sclerosis	3.59e-05	0.000112	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HLA-B—multiple sclerosis	3.56e-05	0.000111	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PGR—multiple sclerosis	3.56e-05	0.000111	CbGpPWpGaD
Mesalazine—CHUK—Disease—CD86—multiple sclerosis	3.52e-05	0.00011	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—POMC—multiple sclerosis	3.52e-05	0.00011	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—IL6—multiple sclerosis	3.52e-05	0.00011	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	3.51e-05	0.00011	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CD4—multiple sclerosis	3.5e-05	0.00011	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CXCR3—multiple sclerosis	3.49e-05	0.000109	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD86—multiple sclerosis	3.46e-05	0.000108	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—IL6—multiple sclerosis	3.46e-05	0.000108	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CD28—multiple sclerosis	3.46e-05	0.000108	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	3.43e-05	0.000107	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—STAT3—multiple sclerosis	3.41e-05	0.000107	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCL3—multiple sclerosis	3.41e-05	0.000107	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCR2—multiple sclerosis	3.4e-05	0.000106	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD40LG—multiple sclerosis	3.39e-05	0.000106	CbGpPWpGaD
Mesalazine—PPARG—Generic Transcription Pathway—MYC—multiple sclerosis	3.36e-05	0.000105	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD8A—multiple sclerosis	3.36e-05	0.000105	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL2RA—multiple sclerosis	3.34e-05	0.000104	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CD4—multiple sclerosis	3.31e-05	0.000104	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HLA-A—multiple sclerosis	3.3e-05	0.000103	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTGER4—multiple sclerosis	3.28e-05	0.000103	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HLA-B—multiple sclerosis	3.23e-05	0.000101	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PGR—multiple sclerosis	3.23e-05	0.000101	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—ALB—multiple sclerosis	3.21e-05	0.0001	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—IL6—multiple sclerosis	3.19e-05	9.99e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CD4—multiple sclerosis	3.18e-05	9.94e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.17e-05	9.91e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CXCR3—multiple sclerosis	3.17e-05	9.91e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—TGFB1—multiple sclerosis	3.16e-05	9.89e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—IL6—multiple sclerosis	3.14e-05	9.82e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CD28—multiple sclerosis	3.14e-05	9.81e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CNR1—multiple sclerosis	3.13e-05	9.81e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CCR5—multiple sclerosis	3.13e-05	9.78e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	3.13e-05	9.78e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—MAPK1—multiple sclerosis	3.1e-05	9.7e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCR2—multiple sclerosis	3.08e-05	9.64e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—HLA-A—multiple sclerosis	3.05e-05	9.53e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL2RA—multiple sclerosis	3.03e-05	9.47e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—TLR4—multiple sclerosis	3.02e-05	9.44e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HLA-DRB1—multiple sclerosis	3.01e-05	9.43e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HLA-A—multiple sclerosis	2.99e-05	9.36e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—BCHE—multiple sclerosis	2.95e-05	9.24e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—TNF—multiple sclerosis	2.95e-05	9.23e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CD28—multiple sclerosis	2.93e-05	9.16e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ICAM1—multiple sclerosis	2.89e-05	9.05e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—APOE—multiple sclerosis	2.84e-05	8.9e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CNR1—multiple sclerosis	2.84e-05	8.89e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CXCL10—multiple sclerosis	2.82e-05	8.83e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD80—multiple sclerosis	2.78e-05	8.71e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—TLR4—multiple sclerosis	2.74e-05	8.56e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HLA-DRB1—multiple sclerosis	2.73e-05	8.55e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.72e-05	8.51e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ICAM1—multiple sclerosis	2.62e-05	8.21e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CD80—multiple sclerosis	2.57e-05	8.04e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—MAPK1—multiple sclerosis	2.57e-05	8.04e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CXCL10—multiple sclerosis	2.56e-05	8.01e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—APOE—multiple sclerosis	2.54e-05	7.94e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD80—multiple sclerosis	2.53e-05	7.9e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.48e-05	7.76e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CD86—multiple sclerosis	2.47e-05	7.72e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCL5—multiple sclerosis	2.43e-05	7.6e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—IL6—multiple sclerosis	2.38e-05	7.45e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—TYK2—multiple sclerosis	2.35e-05	7.36e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—BCHE—multiple sclerosis	2.34e-05	7.34e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—MAPK1—multiple sclerosis	2.33e-05	7.29e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SPP1—multiple sclerosis	2.25e-05	7.04e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CD86—multiple sclerosis	2.24e-05	7e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCL5—multiple sclerosis	2.2e-05	6.89e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IFNG—multiple sclerosis	2.2e-05	6.89e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCR5—multiple sclerosis	2.19e-05	6.85e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—POMC—multiple sclerosis	2.18e-05	6.82e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—TYK2—multiple sclerosis	2.17e-05	6.79e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL2RA—multiple sclerosis	2.16e-05	6.75e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—TYK2—multiple sclerosis	2.13e-05	6.67e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD4—multiple sclerosis	2.13e-05	6.65e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CD86—multiple sclerosis	2.09e-05	6.53e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SPP1—multiple sclerosis	2.04e-05	6.38e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IFNG—multiple sclerosis	2e-05	6.25e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APOE—multiple sclerosis	1.99e-05	6.23e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—ALB—multiple sclerosis	1.99e-05	6.22e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCR5—multiple sclerosis	1.98e-05	6.21e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—IL6—multiple sclerosis	1.97e-05	6.18e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL1B—multiple sclerosis	1.96e-05	6.14e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CD4—multiple sclerosis	1.96e-05	6.14e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL2RA—multiple sclerosis	1.96e-05	6.12e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL2—multiple sclerosis	1.96e-05	6.12e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD4—multiple sclerosis	1.93e-05	6.03e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CCR5—multiple sclerosis	1.85e-05	5.79e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APOE—multiple sclerosis	1.81e-05	5.65e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HLA-A—multiple sclerosis	1.8e-05	5.65e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CD80—multiple sclerosis	1.8e-05	5.63e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—IL6—multiple sclerosis	1.79e-05	5.6e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL1B—multiple sclerosis	1.78e-05	5.57e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—APOE—multiple sclerosis	1.78e-05	5.56e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL2—multiple sclerosis	1.77e-05	5.55e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—POMC—multiple sclerosis	1.71e-05	5.35e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APOE—multiple sclerosis	1.68e-05	5.27e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCL2—multiple sclerosis	1.67e-05	5.24e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—STAT3—multiple sclerosis	1.65e-05	5.15e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CD80—multiple sclerosis	1.63e-05	5.11e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MYC—multiple sclerosis	1.62e-05	5.07e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—POMC—multiple sclerosis	1.55e-05	4.85e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—POMC—multiple sclerosis	1.53e-05	4.78e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CD80—multiple sclerosis	1.52e-05	4.77e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TYK2—multiple sclerosis	1.52e-05	4.76e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—STAT3—multiple sclerosis	1.52e-05	4.76e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCL2—multiple sclerosis	1.52e-05	4.75e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MAPK1—multiple sclerosis	1.5e-05	4.68e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—STAT3—multiple sclerosis	1.49e-05	4.67e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MYC—multiple sclerosis	1.41e-05	4.42e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—APOE—multiple sclerosis	1.41e-05	4.41e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—TGFB1—multiple sclerosis	1.41e-05	4.41e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ALB—multiple sclerosis	1.39e-05	4.35e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MAPK1—multiple sclerosis	1.38e-05	4.32e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TYK2—multiple sclerosis	1.38e-05	4.31e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MAPK1—multiple sclerosis	1.36e-05	4.25e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TYK2—multiple sclerosis	1.29e-05	4.02e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL2—multiple sclerosis	1.26e-05	3.96e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—POMC—multiple sclerosis	1.21e-05	3.79e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MMP9—multiple sclerosis	1.2e-05	3.75e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CD4—multiple sclerosis	1.16e-05	3.64e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL6—multiple sclerosis	1.15e-05	3.6e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL2—multiple sclerosis	1.15e-05	3.59e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ALB—multiple sclerosis	1.1e-05	3.46e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MMP9—multiple sclerosis	1.09e-05	3.4e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—STAT3—multiple sclerosis	1.06e-05	3.33e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—IL6—multiple sclerosis	1.06e-05	3.32e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL6—multiple sclerosis	1.04e-05	3.26e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MYC—multiple sclerosis	9.89e-06	3.09e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TGFB1—multiple sclerosis	9.86e-06	3.09e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAPK1—multiple sclerosis	9.67e-06	3.03e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—STAT3—multiple sclerosis	9.65e-06	3.02e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—STAT3—multiple sclerosis	9e-06	2.82e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MYC—multiple sclerosis	8.97e-06	2.81e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TGFB1—multiple sclerosis	8.94e-06	2.8e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAPK1—multiple sclerosis	8.77e-06	2.74e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MYC—multiple sclerosis	8.36e-06	2.62e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TGFB1—multiple sclerosis	8.34e-06	2.61e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MAPK1—multiple sclerosis	8.18e-06	2.56e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL6—multiple sclerosis	7.43e-06	2.33e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL6—multiple sclerosis	6.74e-06	2.11e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IL6—multiple sclerosis	6.29e-06	1.97e-05	CbGpPWpGaD
